Harrow Health Inc (HROW)
NASDAQ:HROW
Want to see HROW full AI Analyst Report?
HROW Stock Chart & Stats
$41.50
-$0.36(-1.00%)
At close: 4:00 PM EST
$41.50
-$0.36(-1.00%)
Day’s Range― - ―
52-Week Range$21.12 - $54.85
Previous CloseN/A
Volume51.77K
Average Volume (3M)627.80K
Market Cap
$1.50B
Enterprise Value$1.69B
Total Cash (Recent Filing)$72.93M
Total Debt (Recent Filing)$251.98M
Price to Earnings (P/E)68.0
Beta2.29
Next Earnings
May 11, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding37,273,420
10 Day Avg. Volume468,529
30 Day Avg. Volume627,805
Financial Highlights & Ratios
PEG Ratio4.91
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio41.91
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue6.20
Enterprise Value/Gross Profit8.26
Enterprise Value/Ebitda44.33
Forecast
1Y Price Target
$68.50Price Target Upside65.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.47
Revenue Forecast (FY)$351.81M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence DevelopmentAcceptance of scientific abstracts for VEVYE and ILEVRO at a major ophthalmology meeting, combined with planned intravitreal study data for Iheezo, could raise physician awareness and accelerate adoption among retina specialists.
Commercial Expansion And Go-to-marketDoubling sales teams for VEVYE and TRIESENCE, expanding Iheezo into office-based settings, and consolidating products under OneHarrow branding should broaden U.S. coverage and improve market penetration for core therapies.
Reimbursement AccessAssignment of a permanent J-Code for Iopidine removes reimbursement barriers and enables physicians to bill directly for in-office use, making adoption administratively and economically feasible.
Bears Say
Expense And Guidance RiskHigher selling and administrative costs and an acquisition-related research expense drove a bottom-line miss and prompted below-expectation guidance, increasing near-term profitability risk.
Inventory And Sales TimingHigh distributor inventory for Iheezo is delaying the timing of its sales ramp, which can constrain near-term revenue growth despite potential demand.
Limited Revenue ContributionIopidine comprises a small portion of the company’s business, so even meaningful uptake may produce only a modest impact on overall revenue.
Harrow Health News
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $21.12 and its highest was $54.85 in the past 12 months.
What is Harrow Health Inc’s market cap?
Harrow Health Inc’s market cap is $1.50B.
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is May 11, 2026 which is in 5 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on Mar 02, 2026. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.368 by -$0.198.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is -0.35.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 37,273,420 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of $0.17 in its last earnings report, missing expectations of $0.368. Following the earnings report the stock price went down -27.962%.
Which hedge fund is a major shareholder of Harrow Health Inc?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.50 (65.06% Upside)
$68.50 (65.06% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 57.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
72.98%
12-Months-Change
Fundamentals
Return on Equity
-10.00%
Trailing 12-Months
Asset Growth
4.18%
Trailing 12-Months
Company Description
Harrow Health Inc
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Company Deck
HROW Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive outlook: strong 2025 financial performance with double‑digit revenue growth, significant adjusted EBITDA expansion, healthy cash generation, multiple product-specific accelerations (BYOOVIZ, IHEEZO, TRIESENCE, VEVYE), concrete 2026 guidance with clear second‑half weighting, and promising pipeline milestones (G-MELT NDA target, IHEEZO data flow). Near‑term headwinds — Q1 seasonality/channel drawdown, ASC pass‑through loss for IHEEZO, compounding inventory issues, and planned SG&A/R&D investments — are acknowledged and largely presented as manageable or temporary in nature. Given the weight and scale of the positive operating and financial indicators relative to the near-term, addressable challenges, the overall tone is constructive and growth‑oriented.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$68.50
▲(65.06% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
20.06% Insiders
10.27% Mutual Funds
0.58% Other Institutional Investors
58.08% Public Companies and Individual Investors